ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,76
0,00%
Bitcoin
66 929,14
-0,23%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Eterna Therapeutics Inc (ERNA)

  7. Eterna Therapeutics Inc (ERNA) Actualités

ERNA

Eterna Therapeutics (ERNA)

Eterna Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ERNA
DateHeureSourceTitreSymboleSociété
14/05/202423h14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ERNAEterna Therapeutics Inc
10/05/202414h00GlobeNewswire Inc.Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs iNASDAQ:ERNAEterna Therapeutics Inc
08/05/202415h31GlobeNewswire Inc.Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory BoardNASDAQ:ERNAEterna Therapeutics Inc
07/05/202414h00GlobeNewswire Inc.Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M LocusNASDAQ:ERNAEterna Therapeutics Inc
20/02/202414h30GlobeNewswire Inc.Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of DirectorsNASDAQ:ERNAEterna Therapeutics Inc
16/02/202423h30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
16/02/202413h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ERNAEterna Therapeutics Inc
31/01/202413h05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ERNAEterna Therapeutics Inc
24/01/202422h15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ERNAEterna Therapeutics Inc
23/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ERNAEterna Therapeutics Inc
16/01/202422h16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ERNAEterna Therapeutics Inc
12/01/202422h49Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ERNAEterna Therapeutics Inc
03/01/202423h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
03/01/202422h15GlobeNewswire Inc.Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)NASDAQ:ERNAEterna Therapeutics Inc
22/12/202318h05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ERNAEterna Therapeutics Inc
20/12/202322h15GlobeNewswire Inc.Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive OfficerNASDAQ:ERNAEterna Therapeutics Inc
20/12/202321h24Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ERNAEterna Therapeutics Inc
15/12/202300h56GlobeNewswire Inc.Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant FinancingNASDAQ:ERNAEterna Therapeutics Inc
01/11/202313h30GlobeNewswire Inc.Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of DirectorsNASDAQ:ERNAEterna Therapeutics Inc
26/09/202322h30Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ERNAEterna Therapeutics Inc
06/09/202314h00GlobeNewswire Inc.Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell TherapeuticsNASDAQ:ERNAEterna Therapeutics Inc
05/09/202314h30GlobeNewswire Inc.Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of DirectorsNASDAQ:ERNAEterna Therapeutics Inc
26/07/202317h50Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ERNAEterna Therapeutics Inc
18/07/202314h00GlobeNewswire Inc.Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt FinancingNASDAQ:ERNAEterna Therapeutics Inc
11/07/202314h30GlobeNewswire Inc.Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of DirectorsNASDAQ:ERNAEterna Therapeutics Inc
24/05/202314h30GlobeNewswire Inc.Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General CounselNASDAQ:ERNAEterna Therapeutics Inc
17/05/202314h30GlobeNewswire Inc.Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual MeetingNASDAQ:ERNAEterna Therapeutics Inc
11/05/202322h35Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ERNAEterna Therapeutics Inc
10/05/202312h02Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ERNAEterna Therapeutics Inc
05/05/202313h02Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:ERNAEterna Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ERNA

Dernières Valeurs Consultées

BIT
P1U1I8
BNP Paribas Issuance
COIN
BTCHGGBP
UNSW3
KAIKENINUETH
KaikenInu
LSE
0GB2
Magnolia Bostad Ab
IDCM
TRXBTC
TRON
USOTC
FLNCF
Freelancer (QX)
LSE
IRCP
Ishr Ec Irh
TG
BIO
Biotest
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés